A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2011
10/18/2011	US8039019 Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
10/18/2011	US8039018 Solid dosage form of wetted heparin
10/18/2011	US8039010 Glycolic acid-lactic acid copolymer; biocompatible; biodegradable; RNA interference; inhibitors of vascular endothelial growth factor (VEGF); ocular disorders
10/18/2011	US8039009 Modified release formulations of memantine oral dosage forms
10/18/2011	US8039006 Solid composition containing bacillus-type non-pathogenic bacterial spores
10/18/2011	US8038987 Process for the preparation of coated polymer particles
10/18/2011	US8038909 Forming active material of copper/indium/gallium/selenium or sulfur as ink for solar cells by reacting a solution of non-oxide compounds and capping agent; annealing to form nanoparticles 1-500nm diameter; narrow size distribution; close packing; uniformity; polycrystalline; quality; high quality films
10/18/2011	CA2654700C Transdermal patch
10/18/2011	CA2633515C Compositions and methods for dermally treating pain
10/18/2011	CA2633086C Fexofenadine suspension formulation
10/18/2011	CA2535533C Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
10/18/2011	CA2530774C Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
10/18/2011	CA2504199C Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
10/18/2011	CA2494297C Aqueous 2,6-diisopropylphenol pharmaceutical compositions
10/18/2011	CA2487123C Patch containing fentanyl
10/18/2011	CA2470199C Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
10/18/2011	CA2464653C System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
10/18/2011	CA2462345C Dimeric compounds and their use as anti-viral agents
10/18/2011	CA2456806C Methods for micronization of hydrophobic drugs
10/18/2011	CA2456286C Porous matrix comprising cross-linked particles
10/18/2011	CA2453441C Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
10/18/2011	CA2434927C Pharmaceutical compositions with antibiotic activity
10/18/2011	CA2419842C New aporphine esters and their use in therapy
10/18/2011	CA2413692C Method of making particles for use in a pharmaceutical composition
10/18/2011	CA2372099C Antiviral agent in the form of nose drops
10/18/2011	CA2337328C Biocompatible polymers, preparation method and compositions containing same
10/18/2011	CA2228944C Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
10/18/2011	CA2226575C Stabile isotonic lyophilized protein formulation
10/13/2011	WO2011127456A2 Method for formulating large diameter synthetic membrane vesicles
10/13/2011	WO2011127311A1 Low energy, cold process formulation aid
10/13/2011	WO2011127302A2 Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
10/13/2011	WO2011127255A1 Preparation of lipid nanoparticles
10/13/2011	WO2011127252A2 Miniature ingestible device
10/13/2011	WO2011127244A2 ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
10/13/2011	WO2011127241A2 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
10/13/2011	WO2011127236A1 Micro particles for oral delivery in animals
10/13/2011	WO2011127181A2 System and method for the release of nitric oxide using nanoscale media
10/13/2011	WO2011127163A1 Thermally stable oil-in-water emulsions containing an oil that contains polyunsaturated fatty acids
10/13/2011	WO2011127151A2 Combinations of preservatives for ophthalmic compositions
10/13/2011	WO2011127144A1 Methods and compositions for treating wounds utilizing chitosan compounds
10/13/2011	WO2011127139A2 Combinations of preservative compositions for ophthalmic formulations
10/13/2011	WO2011127064A2 Sustained-release reservoir implants for intracameral drug delivery
10/13/2011	WO2011127048A2 NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
10/13/2011	WO2011127010A1 Punctal plugs for controlled release of therapeutic agents
10/13/2011	WO2011126978A1 Sprayable composition comprising high molecular weight charged polymer
10/13/2011	WO2011126910A2 Compositions and methods for the treatment of somatosensory disorders
10/13/2011	WO2011126839A2 Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
10/13/2011	WO2011126810A2 Intravaginal drug delivery device
10/13/2011	WO2011126539A2 Compositions and methods for treatment of mammalian skin
10/13/2011	WO2011126537A2 Oral adhering compositions that apply rhizophora mangle extract in the mouth
10/13/2011	WO2011126368A1 Particle preparation by centrifugal dispersing
10/13/2011	WO2011126352A2 Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof
10/13/2011	WO2011126327A2 Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
10/13/2011	WO2011126294A2 Multi-syringe for producing collagen hydrogel
10/13/2011	WO2011126174A1 Preparation method of curly amyloid fibrils derived from alpha-synuclein, preparation method of hydrogel using same, and using method thereof
10/13/2011	WO2011125943A1 Modified oligonucleotide
10/13/2011	WO2011125910A1 Calcium preparation and production method therefor
10/13/2011	WO2011125848A1 Production method for liposome preparation
10/13/2011	WO2011125798A1 Easily dosable solid preparation
10/13/2011	WO2011125607A1 Method for manufacturing hydrophilic polymer-modified liposomes
10/13/2011	WO2011125500A1 Process for producing granules of fine particles containing sparingly water-soluble drug
10/13/2011	WO2011125091A1 Edible film
10/13/2011	WO2011125015A2 Protease-activatable pore-forming polypeptides
10/13/2011	WO2011124953A2 Controlled release pharmaceutical compositions of tapentadol
10/13/2011	WO2011124876A2 A freeze-dried tablet
10/13/2011	WO2011124739A1 Silica nanoparticles for the intracellular diffusion of poorly soluble bioactive agents
10/13/2011	WO2011124667A2 Process for the preparation of essentially spherical lyophilisates
10/13/2011	WO2011124589A2 Method and device for forming vesicles, in particular using block copolymers
10/13/2011	WO2011124570A2 Oral film formulation
10/13/2011	WO2011124515A1 Method for producing crystalline active ingredient particles
10/13/2011	WO2011124381A1 Fillers comprising gellan or pectin beads
10/13/2011	WO2011124380A1 Chitosan beads and filler comprising such beads
10/13/2011	WO2011124366A1 Piroxicam for prophylactically and therapeutically treating herpes infections
10/13/2011	WO2011124359A1 Release method for implants
10/13/2011	WO2011123916A1 Pharmaceutical composition for the treatment of alzheimer's disease, method for producing same and use thereof
10/13/2011	WO2011087548A3 Therapeutic compositions and methods for targeted delivery of active agents
10/13/2011	WO2011084521A3 Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
10/13/2011	WO2011082980A3 Film coating agents based on combinations of polyvinyl alcohol-polyether graft polymers and polyvinyl alcohol, having an improved moisture barrier effect
10/13/2011	WO2011080741A3 Core stabilized microcapsules, method of their preparation and uses thereof
10/13/2011	WO2011071995A9 Compounds and methods of treating ocular disorders
10/13/2011	WO2011050947A3 Tape, in particular, adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent
10/13/2011	WO2011049309A3 Pharmaceutical composition with both immediate and extended release characteristics
10/13/2011	WO2011044207A3 Compositions containing a high concentration of polar sphingolipid(s)
10/13/2011	WO2011029948A3 Transdermal therapeutic system for administering fentanyl or an analogue thereof
10/13/2011	WO2010146408A4 Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
10/13/2011	WO2010124198A9 Agglomerate formulations useful in dry powder inhalers
10/13/2011	WO2010091822A3 N-hydroxylated amidine-, guanidine- and/or aminohydrazone-type prodrugs for application on the skin
10/13/2011	US20110251677 Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings
10/13/2011	US20110251277 Foamed cleanser with suspended particles
10/13/2011	US20110251244 Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient
10/13/2011	US20110251232 Modified release compositions comprising tacrolimus
10/13/2011	US20110251231 Modified release compositions comprising tacrolimus
10/13/2011	US20110251201 Sustained release intraocular implants and methods for preventing retinal dysfunction
10/13/2011	US20110251146 Topical antifungal composition
10/13/2011	US20110251125 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
10/13/2011	US20110250286 Micro Particles for Oral Delivery in Animals
10/13/2011	US20110250285 Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
10/13/2011	US20110250284 Nanoparticles for Use as Synthetic Platelets and Therapeutic Agent Delivery Vehicles
10/13/2011	US20110250283 Pentablock Polymers
10/13/2011	US20110250282 Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivative

1 ... 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 ... 2991